EASD2017

News
Novo Nordisk HQ flag hires

Novo showcases next-gen GLP-1 at EASD

Novo Nordisk continued to make the case for its once-weekly GLP-1 type 2 diabetes drug semaglutide at this week’s EASD conference in Lisbon, a key drug for the company once approved.